Journal article
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
- Abstract:
-
Background The use of the multicomponent meningococcal vaccine 4CMenB in the UK schedule at 2, 4, and 12 months of age has been shown to be 59·1% effective at preventing invasive group B meningococcal disease. Here, we report the first data on the immunogenicity of this reduced-dose schedule to help to interpret this effectiveness estimate.
Methods In this multicentre, parallel-group, open-label, randomised clinical trial, infants aged up to 13 wee...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Supplementary materials, 397.4KB, Terms of use)
-
(Preview, Version of record, 1.2MB, Terms of use)
-
- Publisher copy:
- 10.1016/S1473-3099(20)30600-9
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Infectious Diseases More from this journal
- Volume:
- 21
- Issue:
- 5
- Pages:
- 688-696
- Publication date:
- 2021-01-08
- Acceptance date:
- 2020-06-19
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Language:
-
English
- Keywords:
- Pubs id:
-
1122301
- Local pid:
-
pubs:1122301
- Deposit date:
-
2020-07-28
Terms of use
- Copyright holder:
- Davis et al.
- Copyright date:
- 2021
- Rights statement:
- Copyright © 2021 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record